CDK9 inhibitors in acute myeloid leukemia

Current treatment for acute myeloid leukemia (AML) is less than optimal, but increased understanding of disease pathobiology and genomics has led to clinical investigation of novel targeted therapies and rational combinations. Targeting the cyclin-dependent kinase 9 (CDK9) pathway, which is dysregul...

Descripción completa

Detalles Bibliográficos
Autores principales: Boffo, Silvia, Damato, Angela, Alfano, Luigi, Giordano, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5824552/
https://www.ncbi.nlm.nih.gov/pubmed/29471852
http://dx.doi.org/10.1186/s13046-018-0704-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5824552/
https://www.ncbi.nlm.nih.gov/pubmed/29471852
http://dx.doi.org/10.1186/s13046-018-0704-8

Ejemplares similares